WORLD NEWS
India News - According to information received by World News, the vaccine of Indian company Bharat Biotech is in demand in the world of Covaxin. The Brazilian Association of Vaccine Clinics (ABCVAC) has tied up with Bharat Biotech. Under this, Brazil will be given 5 million doses of Covaxin. However, this will be finalized after permission from Brazilian health regulator Anvisa.
On 3 January, the Drugs Controller General of India (DCGI) approved the emergency use of Oxford-AstraZeneca's covshield and covaxin
Phase III trials of covaxin are underway. It was already approved for its emergency use. Bharat Biotech has not even mentioned how effective it is. Yes, it is definitely told that it is 100% safe for use. According to the information received by World News, meanwhile, Delhi AIIMS director Dr Randeep Guleria said that antibodies will develop in the body after 2 weeks of taking the second dose.
Kovaxin and Kovshield 100% safe
People will be vaccinated under the vaccination program. The companies have been asked - 'Complete the third phase of the trial and submit the report so that a permanent license can be decided.' DCGI said both vaccines have common or minor side effects. There are mild fever, allergies etc. But both vaccines are 100% safe. Things like being impotent with vaccines are baseless.
According to the information received by World News, it is possible that in the state where the consignment of KoviShield will be sent, Kovaxin should not be sent there. This will not create any confusion during vaccination. For this, standard operating procedure (SOP) will be fixed in two-three days. Both the approved vaccines will take two doses, with the goal of giving vaccines to 300 million people by July.
Kovaxin: 22 thousand people have been vaccinated in the third phase, the results are yet to come
ICMR Director General Prof. Balaram Bhargava said, 'This vaccine is completely safe. The changes made in the virus so far will work on all of them. It is not clear how effective it is. This was completely effective in animal studies. In the first and second phase, 800 people were vaccinated, none of them got corona. The 22,000 people who were vaccinated in the third phase have not shown any side effects so far. Final results are yet to come. '
Coveshield: Half dose up to 90% effective, two full doses up to 62% effective; Average 70%
According to information received by World News, Adar Poonawala, CEO of Serum Institute of India, said, "Now we will give the vaccine only to the government. When we have a permanent license, we can also export, there is no problem. ”In the trial, CoveyShield's Volunteers were given a full half-dose first. Half dose was 90% effective. A full dose was given a month later. When both were given full doses, the effect was reduced to 62%. The average effectiveness of both doses will be 70%.
Vaccination of adults only, later research will be done on those below 18 years
According to information received by World News, according to a senior health ministry official, about 7.5 crore doses of Kovishield and about 10 million doses of Kovaxin are ready. Director General of ICMR Prof. Balaram Bhargava said that only adults in the world are getting vaccinated. Later, research will be done on those below 18 years of age, when the results will be decided to give vaccines to people of this age group.
No comments:
Post a Comment